Science News
from research organizations

Breakthrough in RSV research with drug trial

Date:
August 28, 2014
Source:
Le Bonheur Children's Hospital
Summary:
A new clinical trial of a drug was shown to safely reduce the viral load and clinical illness of healthy adult volunteers intranasally infected with respiratory syncytial virus (RSV). RSV is the most common cause of lower respiratory tract infections in young children in the United States and worldwide. It hospitalizes 125,000 children in the United States each year, and was the cause for 1.5 million outpatient visits.
Share:
       
FULL STORY

The New England Journal of Medicine published research results on Aug. 21 from a clinical trial of a drug shown to safely reduce the viral load and clinical illness of healthy adult volunteers intranasally infected with respiratory syncytial virus (RSV).

Le Bonheur Children's Hospital and the University of Tennessee Health Science Center researcher Infectious Disease Specialist John DeVincenzo, MD, is lead author of this study.

RSV is the most common cause of lower respiratory tract infections in young children in the United States and worldwide. It hospitalizes 125,000 children in the United States each year, and was the cause for 1.5 million outpatient visits, according to the Centers for Disease Control and Prevention (CDC). DeVincenzo and his fellow researchers have been part of virtually every experimental therapeautic advancement, developmental pathway and antiviral therapy created to tackle the virus in the past 15 years.

"No effective antiviral treatment currently exists for RSV, which is the leading cause of severe childhood respiratory infections, and is extremely dangerous for babies and children," said DeVincenzo. "We were pleased that our study, for the first time, shows that the infection caused by the RSV virus can be effectively reduced after the infection has started. This is also the first time to prove that once we reduce the amount of virus in a patient, they begin to feel better very quickly. The next step is to explore clinical trials in naturally infected patients."

The challenge study of Gilead Sciences Inc.'s GS-5806, an investigational oral RSV fusion inhibitor, achieved primary and secondary endpoints of lower viral load, improvements in total mucus weight and symptom diary score compared to placebo. Volunteers in the study were given the oral drug after being infected with RSV using the experimental challenge model. The model is based on a clinical isolate from an infant hospitalized with RSV bronchiolitis which can be safely used to infect adults, and that was developed by DeVincenzo in 2007 to test proof-of-concept antivirals.


Story Source:

The above post is reprinted from materials provided by Le Bonheur Children's Hospital. Note: Materials may be edited for content and length.


Journal Reference:

  1. John P. DeVincenzo, Richard J. Whitley, Richard L. Mackman, Cecilia Scaglioni-Weinlich, Lisa Harrison, Eric Farrell, Stephen McBride, Robert Lambkin-Williams, Robert Jordan, Yan Xin, Srini Ramanathan, Thomas O’Riordan, Sandra A. Lewis, Xiaoming Li, Seth L. Toback, Shao-Lee Lin, Jason W. Chien. Oral GS-5806 Activity in a Respiratory Syncytial Virus Challenge Study. New England Journal of Medicine, 2014; 371 (8): 711 DOI: 10.1056/NEJMoa1401184

Cite This Page:

Le Bonheur Children's Hospital. "Breakthrough in RSV research with drug trial." ScienceDaily. ScienceDaily, 28 August 2014. <www.sciencedaily.com/releases/2014/08/140828170015.htm>.
Le Bonheur Children's Hospital. (2014, August 28). Breakthrough in RSV research with drug trial. ScienceDaily. Retrieved August 2, 2015 from www.sciencedaily.com/releases/2014/08/140828170015.htm
Le Bonheur Children's Hospital. "Breakthrough in RSV research with drug trial." ScienceDaily. www.sciencedaily.com/releases/2014/08/140828170015.htm (accessed August 2, 2015).

Share This Page: